Loading clinical trials...

Corneal Crosslinking for Treatment of Corneal Neovascularization | Clinical Trials | Clareo Health

RECRUITINGPHASE2/PHASE3

Corneal Crosslinking for Treatment of Corneal Neovascularization

Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and/or Infection

NCT04787471•Price Vision Group

View on ClinicalTrials.gov

Summary

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 years of age or older
•With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
•Signed written informed consent.

Exclusion Criteria

•Known sensitivity to treatment medications
•Current condition that in the investigator's opinion could compromise safety or data integrity.
•Pregnancy (including plan to become pregnant) or lactation during the course of the study

Locations (1)

Price Vision Group

Indianapolis, Indiana, United States

Key Dates

Start Date

May 3, 2021

Primary Completion Date

July 15, 2026

Completion Date

September 15, 2026

Last Updated

July 31, 2025

Enrollment

ESTIMATED participants

Conditions

Corneal Neovascularization

Interventions

30 minute photoactivation of riboflavin 0.1%

COMBINATION_PRODUCT

10 minute photoactivation of riboflavin 0.1%

COMBINATION_PRODUCT

Contacts

Marianne Price, PhD

CONTACT

317-814-2990 mprice@cornea.org

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

NCT00555594

Corneal Neovascularization

View study

UNKNOWN

Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.

NCT05659940

Corneal NeovascularizationNeutrophils

View study

TERMINATED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 31, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Corneal Crosslinking for Treatment of Corneal Neovascularization

Inclusion Criteria

Exclusion Criteria

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.

Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

Corneal Thinning During Topical Bevacizumab Therapy